GSK Appoints CSO and President, R&DBy
GlaxoSmithKline has appointed Dr. Hal Barron as chief scientific officer, president, research and development (R&D), and executive director to the GSK Board of Directors. Barron will assume his new role and join the board on January 1, 2018.
Barron is currently president R&D at Calico (California Life Sciences), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to joining Calico, Barron was executive vice president, head of Global Product Development, and chief medical officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech, a Roche company. At Genentech, he was senior vice president of development and chief medical officer.
During his time at Genentech and Roche, Barron oversaw the development of several drugs: Xolair (omalizumab), Avastin (bevacizumab), Tarceva (erlotinib), Lucentis (ranibizumab), Actemra (tocilizumab), Zelboraf (vemurafenib), Erivedge (vismodegib), Perjeta (pertuzumab), Kadcyla (trastuzumab emtansine) as well as Gazyva (obinutuzumab).
Barron will be based in the US while operating from offices in both San Francisco and Stevenage in the UK. The new office in San Francisco will be focused on business development for R&D.